MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma

Cancer Letters

Volumn 303, Issue 1, 2011, Pages 56-64

  Bray, Isabella ^a,b   Tivnan, Amanda ^a,b   Bryan, Kenneth ^a,b   Foley, Niamh H ^a,b   Watters, Karen M ^a,b   Tracey, Lorraine ^c   Davidoff, Andrew M ^c,d   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

MicroRNAs; MiR 542 5p; Neuroblastoma; Orthotopic mouse model

Indexed keywords

MICRORNA; MICRORNA 542 5P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; CELL CULTURE TECHNIQUES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICROARRAY ANALYSIS; MICRORNAS; NEUROBLASTOMA; RISK FACTORS; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 79951850875     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.016     Document Type: Article

References (25)

1. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
2. Duursma A.M., Kedde M., Schrier M., Le Sage C., Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008, 14:872-877.
3. Orom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5' UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 2008, 30:460-471.
4. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. USA. 2008, 105:1608-1613.
5. Buckley P.G., Alcock L., Bryan K., Bray I., Schulte J.H., Schramm A., Eggert A., Mestdagh P., De Preter K., Vandesompele J., Speleman F., Stallings R.L. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin. Cancer Res. 2010, 16:2971-2978.
6. Mestdagh P., Fredlund E., Pattyn F., Schulte J.H., Muth D., Vermeulen J., Kumps C., Schlierf S., De Preter K., Van Roy N., Noguera R., Laureys G., Schramm A., Eggert A., Westermann F., Speleman F., Vandesompele J. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010, 29:1394-1404.
7. Schulte J.H., Schowe B., Mestdagh P., Kaderali L., Kalaghatgi P., Schlierf S., Vermeulen J., Brockmeyer B., Pajtler K., Thor T., de Preter K., Speleman F., Morik K., Eggert A., Vandesompele J., Schramm A. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int. J. Cancer 2010.
8. Stallings R.L., Foley N.H., Bryan K., Buckley P.G., Bray I. Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin. Ther. Targets 2010.
9. Hoehner J.C., Gestblom C., Hedborg F., Sandstedt B., Olsen L., Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors progress along an extra-adrenal chromaffin lineage. Lab. Invest. 1996, 75:659-675.
10. Stallings R.L., Howard J., Dunlop A., Mullarkey M., McDermott M., Breatnach F., O'Meara A. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?. Cancer Genet. Cytogenet. 2003, 140:133-137.
11. Bray I., Bryan K., Prenter S., Buckley P.G., Foley N.H., Murphy D.M., Alcock L., Mestdagh P., Vandesompele J., Speleman F., London W.B., McGrady P.W., Higgins D.G., O'Meara A., O'Sullivan M., Stallings R.L. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009, 4:e7850.
12. Chen Y., Stallings R.L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007, 67:976-983.
13. Cole K.A., Attiyeh E.F., Mosse Y.P., Laquaglia M.J., Diskin S.J., Brodeur G.M., Maris J.M. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 2008, 6:735-742.
14. Foley N.H., Bray I.M., Tivnan A., Bryan K., Murphy D.M., Buckley P.G., Ryan J., O'Meara A., O'Sullivan M., Stallings R.L. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol. Cancer 2010, 9:83.
15. Fontana L., Fiori M.E., Albini S., Cifaldi L., Giovinazzi S., Forloni M., Boldrini R., Donfrancesco A., Federici V., Giacomini P., Peschle C., Fruci D. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008, 3:e2236.
16. Wei J.S., Song Y.K., Durinck S., Chen Q.R., Cheuk A.T., Tsang P., Zhang Q., Thiele C.J., Slack A., Shohet J., Khan J. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008, 27:5204-5213.
17. Welch C., Chen Y., Stallings R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26:5017-5022.
18. Tivnan A., Foley N.H., Tracey L., Davidoff A.M., Stallings R.L. MicroRNA-184-mediated inhibition of tumor growth in an orthotopic murine model of neuroblastoma. Anticancer Res. 2010, 30:4391-4395.
19. Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
20. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
21. Dickson P.V., Hamner B., Ng C.Y., Hall M.M., Zhou J., Hargrove P.W., McCarville M.B., Davidoff A.M. In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J. Pediatr. Surg. 2007, 42:1172-1179.
22. Gao C.F., Xie Q., Su Y.L., Koeman J., Khoo S.K., Gustafson M., Knudsen B.S., Hay R., Shinomiya N., Vande Woude G.F. Proliferation and invasion: plasticity in tumor cells. Proc. Natl. Acad. Sci. USA. 2005, 102:10528-10533.
23. Attiyeh E.F., London W.B., Mosse Y.P., Wang Q., Winter C., Khazi D., McGrady P.W., Seeger R.C., Look A.T., Shimada H., Brodeur G.M., Cohn S.L., Matthay K.K., Maris J.M. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 2005, 353:2243-2253.
24. Damiano L., Di Stefano P., Camacho Leal M.P., Barba M., Mainiero F., Cabodi S., Tordella L., Sapino A., Castellano I., Canel M., Frame M., Turco E., Defilippi P. p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumor cell scatter and proliferation. Oncogene 2010, 29:3677-3690.
25. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., Mendell J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.